Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study
Digestion · 2024
DOI: 10.1159/000540420 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Digestion, 2024. Verfasst von Yanli Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Irritable Bowel Syndrome, Gastrointestinal Microbiome, Quality of Life. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
The imbalance in gut microbiota is contributing to the development and progression of IBS. FMT can improve the gut microbiota, and donor-recipient-matched FMT can help develop individualized treatment plans according to different enterotypes. This study aimed to explore the efficacy of donor-recipient-matched FMT in IBS with predominant diarrhoea (IBS-D) and evaluate its effects on gut microbiota.
Methods
Twenty-seven patients with IBS-D were randomly divided into donor-recipient-matched FMT group (group P), random-donor FMT group (group R), and placebo group (group B). All participants received corresponding FMT treatment after filling in IBS-S, IBS-QoL, GSRS, and HADS questionnaires and having their stool samples collected at 4, 8, and 12 weeks after treatment. The improvement in the symptoms and the changes in the bacterial flora were analysed for three groups.
Results
The IBS-SSS, IBS-QoL, GSRS, and anxiety scores of group P were significantly lower after treatment (p < 0.05). The IBS-QoL scores of group R were significantly lower after treatment (p < 0.05). Beta diversity analysis showed that the gut microbiota of group P had an obvious trend of classification after treatment. Seven bacterial genera were related to the differences in the IBS-SSS scores before and after treatment.
Conclusion
Donor-recipient-matched FMT significantly improved the clinical symptoms, quality of life, and anxiety scores of the patients with IBS-D than random-donor FMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, China.
- Center for Research and Development, Xiamen Treatgut Biotechnology Co., Ltd., Xiamen, China.
Zitieren
APA
Zhang, Y., Wang, S., Wang, H., Cao, M., Wang, M., Zhang, B., Xiao, C., Zhu, H., & Du, S. (2024). Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study. Digestion. https://doi.org/10.1159/000540420
Vancouver
Zhang Y, Wang S, Wang H, Cao M, Wang M, Zhang B, et al. Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study. Digestion. 2024. doi:10.1159/000540420
BibTeX
@article{Zhang2024,
author = {Zhang, Yanli and Wang, Shuai and Wang, Huifen and Cao, Man and Wang, Miao and Zhang, Bangzhou and Xiao, Chuanxing and Zhu, Huiting and Du, Shiyu},
title = {Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study},
journal = {Digestion},
year = {2024},
doi = {10.1159/000540420}
}
EUVIMED